Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients

Tolvaptan, a vasopressin V<sub>2</sub> receptor antagonist, was initially approved in Japan for treatment of autosomal dominant polycystic kidney disease (ADPKD). Recently, a retrospective study showed that the effect of tolvaptan on kidney function could be sustained for a long period....

Descripción completa

Detalles Bibliográficos
Autores principales: Nakatani, Shinya, Ishimura, Eiji, Machiba, Yuri, Fujimoto, Kenta, Uedono, Hideki, Tsuda, Akihiro, Mori, Katsuhito, Emoto, Masanori, Inaba, Masaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098338/
https://www.ncbi.nlm.nih.gov/pubmed/32232055
http://dx.doi.org/10.1159/000506118

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098338/
https://www.ncbi.nlm.nih.gov/pubmed/32232055
http://dx.doi.org/10.1159/000506118

Ejemplares similares